MedTrace Logo

Empagliflozin Versus Non-SGLT2 Oral Drugs for Blood Pressure in Type 2 Diabetes

NCT07541456 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 300

Last updated 2026-04-21

No results posted yet for this study

Summary

This randomized controlled trial studied whether empagliflozin lowers blood pressure better than non-SGLT2 oral hypoglycemic treatment in adults with type 2 diabetes mellitus and hypertension. A total of 300 participants were assigned to 1 of 2 treatment groups and followed for 12 weeks. One group received empagliflozin and the other received non-SGLT2 oral therapy. Blood pressure was measured at baseline and again after 12 weeks to compare the effect of treatment on systolic and diastolic blood pressure.

Conditions

Interventions

DRUG

Empagliflozin

Empagliflozin 10 mg once daily for the first 4 weeks, increased to 25 mg once daily until week 12.

DRUG

Metformin

Metformin 500 mg twice daily for 12 weeks.

Sponsors & Collaborators

  • Dr. Zarmina Younes

    lead OTHER

Principal Investigators

  • Zarmina Younes · Department of Internal Medicine, Shahida Islam Teaching Hospital, Lodhran, Pakistan

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
20 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-06-09
Primary Completion
2025-11-08
Completion
2025-11-08

Countries

  • Pakistan

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07541456 on ClinicalTrials.gov